NasdaqGS:PRAXBiotechs
Praxis Precision Medicines (PRAX) Wins FDA Breakthrough Tag As CNS Pipeline Advances
Praxis Precision Medicines (NasdaqGS: PRAX) reported new clinical and regulatory milestones across its central nervous system pipeline, including progress on several drug candidates.
The company received FDA Breakthrough Therapy designation for Elsunersen, its investigational treatment for neurological disorders.
Praxis expanded its CNS program through collaborations and licensing agreements with partners including RogCon Inc. and Ionis Pharmaceuticals.
This kind of pipeline and partnership...